Mylan Is Latest Entrant On US Generic Suboxone
Mylan has joined Alvogen, Dr Reddy’s and Sandoz in the battle over US generic versions of Indivior’s Suboxone sublingual film. However, it is only marketing two of the four strengths offered by its rivals.
You may also be interested in...
Alvogen and Dr Reddy’s do not infringe key patents protecting Indivior’s Suboxone Film, the US Court of Appeals has confirmed. But Teva continues to fall foul of a production patent running until 2024.
The CEO of Swedish addiction and pain specialist Orexo tells Scrip its top drug Zubsolv will grow strongly in coming years to address the opioid crisis in the US, and that revenues will be further boosted by novel pipeline therapies likely to be commercialized in coming years.
Alvogen and Dr Reddy’s have launched generic versions of Indivior’s Suboxone in the US, after the Supreme Court denied the originator’s attempt to further frustrate generic launches. But these two versions will compete with an authorized generic launched by Indivior through Sandoz.